Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in mice.

Abstract

Bis-[(p-methoxybenzyl)cyclopentadienyl] titanium dichloride, better known as Titanocene Y, is a newly synthesized transition metal-based anticancer drug. We studied the antitumor activity of Titanocene Y with concentrations of 2.1, 21 and 210 micromol/l against a freshly explanted human breast cancer, using an in-vitro soft agar cloning system. The sensitivity against Titanocene Y was highly remarkable in the breast cancer tumor in the full concentration range. Titanocene Y showed cell death induction at 2.1 micromol/l, well comparable to cisplatin, given at a concentration of 1.0 micromol/l. A further preclinical development of Titanocene Y was warranted and therefore an MCF-7 human breast cancer xenograft nonobese diabetic/severe combined immunodeficient mouse model was used. Titanocene Y was given for 21 days at 30 mg/kg/day (75% of the maximum tolerable dose of Titanocene Y), which resulted in the reduction of the tumor volume to around one-third, whereas no mouse was lost because of the surprisingly low toxicity of Titanocene Y.

• Authors: Philipp Beckhove, Olaf Oberschmidt, Axel R Hanauske, Clara Pampillón, Volker Schirrmacher, Nigel J Sweeney, Katja Strohfeldt, Matthias Tacke
• Journal: Anti-cancer drugs (Anticancer Drugs) Vol. 18 Issue 3 Pg. 311-5 (Mar 2007) ISSN: 0959-4973 [Print] England
• PMID: 17264764 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Organometallic Compounds
• Titanocene Y
• Agar
• Cisplatin

Topics

• Agar
• Animals
• Antineoplastic Agents (adverse effects, therapeutic use)
• Breast Neoplasms (drug therapy)
• Cell Line, Tumor
• Cisplatin (therapeutic use)
• Female
• Humans
• Mice
• Neoplasm Transplantation
• Organ Culture Techniques
• Organometallic Compounds (adverse effects, therapeutic use)
• Xenograft Model Antitumor Assays